An interventional study of Demonstration of applying triamcinolone cream and Mobile App Use in Atopic Dermatitis, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Health services research
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.
Unlike most modes of medication administration, topical medications do not have a standardized method of dosage administration] Although qualitative administration measures exist, these measures are often arbitrary and not quantifiable (i.e., "a fingertip"). In such cases, inappropriate dosing (i.e., using too much or too little) is an essential cause of treatment failure, and measurements of adherence for topical medications should consider the amount of medication administered. In a study analyzing the response to treatment in psoriatic patients, patients who received a standardized dose of topical calcipotriol achieved a more significant decrease in mean Psoriasis Area and Severity Index (PASI) (47%) compared to patients who were not standardized (17%, P\<0.0001). Moreover, over two-thirds of psoriatic patients deemed initially poor responders in the standardized regimen group were considered responsive to treatment after further consideration.
Given topical options' low cost, efficacy, and excellent safety profiles, they are the first line treatment option for mild-to-moderate Atopic Dermatitis (AD) treatment. This study will aim to assess differences in the amount of medication dispensed in two groups of patients with atopic dermatitis. The first will undergo a brief educational demonstration by a trained professional to highlight the appropriate amount of topical medication to dispense for their disease involvement. The second group will be a control group and receive the same medication; however, the Participants will receive standard of care education (verbal and written instructions) only. Data from the two groups will be collected and analyzed to measure trends in dosing (i.e., if the correct dosage quantity and frequency was dispensed).
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 30 is below the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observe a live demonstration instructing how to dispense 1 fingertip unit (FTU) of medication (triamcinolone cream) per 1% body surface area
Other: Demonstration of applying triamcinolone cream
Additional mobile application that provides instructions to apply the medication (triamcinolone cream)
Behavioral: Mobile App Use
Standard of care written/verbal instructions only
Other: Standard of Care
Live demonstration of applying 1 fingertip unit of triamcinolone cream
Additional mobile application that provides amount dispensed and adherence data.
Written/verbal instructions only
Amount of Topical Medication Dispensed - Demonstration Group
Amount of Topical Medication Dispensed in grams
Time frame: Day 7
Amount of Topical Medication Dispensed - Standard of Care Group
Amount of Topical Medication Dispensed in grams
Time frame: Day 7
Amount of Topical Medication Dispensed - Mobile Application Group
Amount of Topical Medication Dispensed in grams
Time frame: Day 7
Number of times of Application - Demonstration Group
Frequency of Application
Time frame: Day 7
Number of times of Application - Standard of Care Group
Frequency of Application
Time frame: Day 7
Number of times of Application - Mobile Application Group
Frequency of Application
Time frame: Day 7
Change in Investigator Global Assessment (IGA) Scores
The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 2 is mild, 3 is moderate, and 4 indicates severe AD. A decrease in score relates to an improvement in signs and symptoms.
Time frame: Baseline and Day 7
Change in Percentage of Body Surface Area (BSA) affected
Body Surface Area percentage = 0.007184 x (Height(cm)\^0.725) x (Weight(kg)\^0.425)
Time frame: Baseline and Day 7
Subject Questionnaire Scores
a brief questionnaire will be distributed to gain insight into attitudes towards medication samples and educational demonstrations.
Time frame: Day 7
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →